

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4622500

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
XAVIER JACQ	02/03/2017
QUENTIN GUERANGER	02/06/2017
JEANNIE ANN HARRIGAN	02/07/2017
RECEIVING PARTY DATA	
Name:	MISSION THERAPEUTICS LIMITED
Street Address:	BABRAHAM RESEARCH CAMPUS
Internal Address:	MONETA (BUILDING 280)
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB22 3AT
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15318452
CORRESPONDENCE DATA	
Fax Number:	(973)596-0545
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9735964500
Email:	IPDocket@gibbonslaw.com
Correspondent Name:	SAMUEL H. MEGERDITCHIAN
Address Line 1:	ONE GATEWAY CENTER
Address Line 4:	NEWARK, NEW JERSEY 07102-5310
ATTORNEY DOCKET NUMBER:	114683-95501 (P003)
NAME OF SUBMITTER:	SAMUEL H. MEGERDITCHIAN
SIGNATURE:	/Samuel H. Megerditchian/
DATE SIGNED:	10/02/2017
Total Attachments: 4	
source=114683-95501 - Assignment#page1.tif	
source=114683-95501 - Assignment#page2.tif	
source=114683-95501 - Assignment#page3.tif	

ASSIGNMENT

WHEREAS We, the below named inventors, [hereinafter referred to as "Assignors"], have made an invention entitled:

METHODOLOGIES FOR MEASURING ISOPEPTIDASE ACTIVITY IN BIOLOGICAL SAMPLES IN A HIGH THROUGHPUT MANNER

for which We executed an application for United States Letters Patent filed in the U.S. Patent and Trademark Office (USPTO) filed concurrently herewith or identified by **U.S. Application No. 15/318,452, filed on December 13, 2016**, as the U.S. national phase entry of International Application No. PCT/GB2015/051752, filed on June 15, 2015; and

WHEREAS, **MISSION THERAPEUTICS LIMITED**, a corporation of the United Kingdom whose post office address is **Babraham Research Campus, Moneta (Building 280), Cambridge CB22 3AT, UNITED KINGDOM** (hereinafter referred to as "Assignee"), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, including the entire right, title, and interest in and to the above-referenced U.S. application and the United States Letters Patent to be issued upon this application or any application claiming priority to this application, and the entire right, title, and interest in and to International Application No. PCT/GB2015/051752, filed on June 15, 2015, and United Kingdom Patent Application No. 1410653.8, filed on June 14, 2014;

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, We, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced U.S. application, and all other non-provisional applications, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority on the basis of the above-referenced U.S. application, and all applications for Letters Patent which may hereafter be filed for this invention in any foreign country, including International Application No. PCT/GB2015/051752, filed on June 15, 2015, and United Kingdom Patent Application No. 1410653.8, filed on June 14, 2014, and all Letters Patent which may be granted on this invention in any foreign country, and all extensions, renewals, and reissues thereof; and We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;


AND, WE HEREBY further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all non-provisional, divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

Name: Xavier JACQ
Address: Babraham Research Campus
Moneta (Building 280)
Cambridge CB22 3AT, UNITED KINGDOM

Signature: _____
Date: _____


Witness: _____
Signature: _____


Name: Quentin GUERANGER
Address: Babraham Research Campus
Moneta (Building 280)
Cambridge CB22 3AT, UNITED KINGDOM

Signature: 
Date: 06.02.17

Witness:  Aurélie LeFevre
Signature: _____

Name: Jeanine Ann HARRIGAN
Address: Babraham Research Campus
Moneta (Building 280)
Cambridge CB22 3AT, UNITED KINGDOM

Signature: 
Date: 07/02/17

Witness: Dr Mark Ian Kemp
Signature: 

ASSIGNMENT

WHEREAS We, the below named inventors, [hereinafter referred to as "Assignors"], have made an invention entitled:

METHODOLOGIES FOR MEASURING ISOPEPTIDASE ACTIVITY IN BIOLOGICAL SAMPLES IN A HIGH THROUGHPUT MANNER


for which We executed an application for United States Letters Patent filed in the U.S. Patent and Trademark Office (USPTO) filed concurrently herewith or identified by **U.S. Application No. 15/318,452, filed on December 13, 2016**, as the U.S. national phase entry of International Application No. PCT/GB2015/051752, filed on June 15, 2015; and


WHEREAS, **MISSION THERAPEUTICS LIMITED**, a corporation of the United Kingdom whose post office address is **Babraham Research Campus, Moneta (Building 280), Cambridge CB22 3AT, UNITED KINGDOM** (hereinafter referred to as "Assignee"), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, including the entire right, title, and interest in and to the above-referenced U.S. application and the United States Letters Patent to be issued upon this application or any application claiming priority to this application, and the entire right, title, and interest in and to International Application No. PCT/GB2015/051752, filed on June 15, 2015, and United Kingdom Patent Application No. 1410653.8, filed on June 14, 2014;

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, We, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced U.S. application, and all other non-provisional applications, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority on the basis of the above-referenced U.S. application, and all applications for Letters Patent which may hereafter be filed for this invention in any foreign country, including International Application No. PCT/GB2015/051752, filed on June 15, 2015, and United Kingdom Patent Application No. 1410653.8, filed on June 14, 2014, and all Letters Patent which may be granted on this invention in any foreign country, and all extensions, renewals, and reissues thereof; and We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all non-provisional, divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

Name: Xavier JACQ
Address: Babraham Research Campus
Moneta (Building 280)
Cambridge CB22 3AT, UNITED KINGDOM
Signature: 
Date: 03.02.2017

Witness: GENTILLOTTI, Anne
Signature: 

Name: Quentin GUERANGER
Address: Babraham Research Campus
Moneta (Building 280)
Cambridge CB22 3AT, UNITED KINGDOM
Signature: _____
Date: _____

Witness: _____
Signature: _____

Name: Jeanine Ann HARRIGAN
Address: Babraham Research Campus
Moneta (Building 280)
Cambridge CB22 3AT, UNITED KINGDOM
Signature: _____
Date: _____

Witness: _____
Signature: _____